Yes, breast cancer can spread to the ovaries, and it does so more often than many people realize. Autopsy and surgical studies have found ovarian metastases in 17% to 47% of patients previously treated for breast cancer. In living patients, the spread is often discovered incidentally during surgery or imaging for other reasons, because ovarian metastases typically cause no symptoms until they grow large enough to press on surrounding structures or cause fluid buildup in the abdomen.
How Common Is Ovarian Spread?
Among all cancers that metastasize to the ovaries, breast cancer is the second most common source, responsible for roughly 13% to 28% of secondary ovarian tumors. The gastrointestinal tract, particularly colorectal cancer, accounts for the largest share. Overall, metastatic tumors from other organs make up 5% to 30% of all ovarian malignancies, meaning that not every ovarian mass in a breast cancer patient is a new, separate cancer. It could be spread from the original breast tumor.
Carriers of BRCA1 or BRCA2 gene mutations face a higher risk. Breast cancer metastasis to the ovaries has been reported in 10% to 30% of BRCA mutation carriers, and the prognosis tends to be worse in this group. Adding to the complexity, BRCA carriers also have an elevated risk of developing a completely separate primary ovarian cancer, making it critical to determine whether an ovarian tumor is new or a sign of breast cancer spread.
Which Breast Cancer Types Are More Likely to Spread
Invasive lobular carcinoma, which accounts for about 10% to 15% of all breast cancers, has a well-documented tendency to metastasize to unusual sites, including the ovaries and the lining of the abdominal cavity. Invasive ductal carcinoma, the more common type, can also spread to the ovaries, but lobular carcinoma does so at disproportionately higher rates. Researchers are still working to understand why lobular cells favor these destinations, but the pattern is consistent enough that oncologists monitor lobular breast cancer patients with this possibility in mind.
How Breast Cancer Reaches the Ovaries
Cancer cells spread through a multi-step process. First, cells break away from the original breast tumor and enter either the bloodstream or the lymphatic system. Once circulating, they evade the immune system, attach to blood vessel walls near the ovary, and push through into the tissue. There, if conditions are favorable, they establish a new colony and recruit their own blood supply to fuel growth. For breast cancer specifically, spread through the bloodstream (hematogenous spread) is the primary route to the ovaries, as opposed to direct surface-level spread within the abdominal cavity, which is more typical of cancers that start in the digestive tract.
Symptoms and How It’s Found
Ovarian metastases from breast cancer are generally silent in their early stages. They often show up as bilateral (affecting both ovaries), solid, small masses that produce no pain or noticeable changes. By the time symptoms do appear, the tumor has usually grown significantly. The most common signs at that point include abdominal swelling from fluid accumulation (ascites), pelvic pressure or pain, and bloating. In one documented case, imaging revealed an ovarian tumor measuring 11 centimeters alongside a large volume of abdominal fluid.
Blood tests can offer clues. A protein called CA-125, commonly elevated in ovarian cancer, may also rise when breast cancer spreads to the ovaries. Another marker, CA 15-3, is more closely associated with breast cancer. When both are elevated in a patient with a breast cancer history, it raises suspicion for metastatic spread rather than a new ovarian cancer.
Telling It Apart From Primary Ovarian Cancer
This is one of the trickiest diagnostic challenges. Under the microscope, metastatic breast cancer in the ovary can look very similar to a cancer that started there. In some cases, even experienced pathologists cannot determine the tumor’s origin during surgery. The key tool for solving this puzzle is a lab technique called immunohistochemistry, which uses specific antibody stains to identify where a cancer cell originated.
Two markers are particularly useful for confirming breast origin. GATA3 detects breast cancer cells with about 96% sensitivity, making it the most reliable option. Another marker called GCDFP-15 is less sensitive (around 69%) but highly specific at 97%, meaning that when it’s positive, you can be very confident the tumor came from the breast. On the other side, a marker called PAX8 is positive in nearly 100% of primary ovarian cancers but negative in tumors that originated elsewhere. So a PAX8-negative, GATA3-positive ovarian tumor strongly points to metastatic breast cancer.
Getting this distinction right matters enormously, because the treatment for metastatic breast cancer in the ovary is fundamentally different from treatment for a new primary ovarian cancer.
Prognosis After Ovarian Spread
A diagnosis of ovarian metastasis from breast cancer signals advanced disease, and the outlook reflects that reality. The five-year survival rate ranges from 6% to 26%. In one large study published in Frontiers in Oncology, the median overall survival after discovery of ovarian metastasis was 28 months, though the median survival from the original breast cancer diagnosis was considerably longer at 85 months, reflecting the time gap between the initial cancer and the appearance of ovarian spread.
Progression-free survival, the period during which the cancer doesn’t worsen, also differs dramatically depending on findings at surgery. Patients whose removed ovaries showed no cancer deposits had a median progression-free survival of 29 months, compared to just 8 months for those whose ovaries contained metastatic tumor. The presence of ovarian metastasis in the surgical specimen is itself considered a negative prognostic sign.
Role of Ovarian Removal
Surgical removal of the ovaries plays a dual role in metastatic breast cancer. For hormone receptor-positive breast cancers, removing the ovaries eliminates a major source of estrogen, which can fuel cancer growth. This is why oophorectomy (ovary removal) has long been used as a hormonal treatment strategy, separate from the question of whether the ovaries themselves contain cancer.
Research comparing different surgical approaches found that removing both the ovaries and the fallopian tubes together yielded better outcomes than removing the ovaries alone. The combined procedure was associated with a median overall survival of about 41 months, compared to 26 months for ovary-only removal. This difference was statistically significant and has influenced surgical planning for these patients. Removing the fallopian tubes may eliminate an additional site where microscopic disease can hide, though the exact reason for the survival benefit is still being studied.
For BRCA mutation carriers who have completed childbearing, preventive removal of the ovaries and fallopian tubes is often recommended even without evidence of spread, both to reduce ovarian cancer risk and to lower estrogen-driven breast cancer recurrence.